Curia Deal Moves NCT Toward Commercial Production

TLDR

• EXOZ falls 4.86% to $6.50 after eXoZymes signs its Curia manufacturing deal.
• Curia will scale NCT work across facilities in León, Spain, and Rozzano, Italy.
• The Q4 2026 program will map a route toward larger-scale NCT production in 2027.
• Technology transfer covers enzyme fermentation, cell-free reaction and purification.
• eXoZymes aims to use Curia’s manufacturing network to support future NCT supply.

eXoZymes traded at $6.50, down 4.86%, after the company announced a commercial-scale manufacturing agreement with Curia Global. The deal advances NCT beyond pilot-scale validation and starts a formal technology transfer program during the fourth quarter of 2026. eXoZymes plans to use Curia’s European manufacturing network to prepare NCT for larger-scale production and possible commercialization during 2027.

eXoZymes, Inc., EXOZ

Curia Agreement Advances NCT Manufacturing

eXoZymes will transfer its proprietary NCT manufacturing process to Curia under the newly signed commercial-scale development and manufacturing agreement. Curia will scale the process in León, Spain, and Rozzano, Italy, giving the program access to two manufacturing sites. The companies will focus on process transfer, technical validation, engineering work, and production planning before any broader commercial manufacturing begins.

The program will cross validate enzyme fermentation, cell-free reaction, and purification processes that form eXoZymes’ integrated NCT platform. Curia will also conduct process modeling and engineering analysis to identify equipment, operating conditions, and requirements for larger manufacturing runs. These activities should establish a technical roadmap for scaling NCT while reducing execution risks between pilot operations and commercial production.

The agreement follows eXoZymes’ earlier pilot-scale work, which demonstrated the NCT process and improved both productivity and production economics. Management now wants to move the entire integrated process into a commercial manufacturing environment with established development and manufacturing infrastructure. The transition marks a key operational step because successful transfer could support customer qualification, supply planning, and later commercial agreements.

Q4 Program Builds Path Toward 2027 Production

eXoZymes expects the Curia program to begin during the fourth quarter of 2026 and continue through key technical transfer activities. The companies will use those results to define the recommended route toward larger-scale NCT manufacturing during the following year. That schedule makes 2027 the next major production milestone, although the announcement provides no specific commercial launch date.

Curia operates more than 20 global sites and employs over 3,000 people across its contract research and manufacturing network. Its services cover process development, analytics, drug substance manufacturing, biologics, generic active ingredients, and sterile fill-finish production. The León and Rozzano sites will support technology transfer, process development, scale-up analysis, and NCT manufacturing preparation.

eXoZymes gains access to established manufacturing systems without building equivalent large-scale facilities entirely through its own capital spending. However, the program focuses on technology transfer and manufacturing preparation, rather than immediate commercial production or defined customer supply volumes. Its value will depend on successful validation, reliable scale-up, and a workable production pathway that meets future commercial requirements.

eXoZymes Expands Its Cell-Free Product Pipeline

Founded in 2019, eXoZymes develops a cell-free biomanufacturing platform that uses engineered enzymes to produce high-value molecules outside living cells. The company aims to replace inefficient extraction and petrochemical processes with scalable manufacturing routes for nutraceutical and pharmaceutical products. NCT represents one part of that strategy, while the company also develops cannabinoid analogs, santalene, and other natural-product molecules.

The company plans several commercialization paths, including partnerships, licensing agreements, joint ventures, and direct manufacturing relationships where appropriate. The Curia agreement tests whether eXoZymes can transfer laboratory and pilot processes into established manufacturing environments. A successful NCT scale-up could also provide a template for moving other molecules through similar development and production stages.

EXOZ shares fell despite the announcement, so the market did not immediately translate the agreement into a positive price reaction. The $6.50 price also reflects market expectations around execution, commercialization timing, funding needs, and future customer demand for NCT. For now, the Curia program gives eXoZymes a defined manufacturing path, while 2027 remains the next important operational milestone.

The post eXoZymes (EXOZ) Stock: Curia Deal Moves NCT Toward Commercial Production appeared first on Blockonomi.

Source: https://blockonomi.com/exozymes-exoz-stock-curia-deal-moves-nct-toward-commercial-production/